PT3193867T - Formulações oculares para administração de fármaco e proteção do segmento anterior do olho - Google Patents

Formulações oculares para administração de fármaco e proteção do segmento anterior do olho

Info

Publication number
PT3193867T
PT3193867T PT158416206T PT15841620T PT3193867T PT 3193867 T PT3193867 T PT 3193867T PT 158416206 T PT158416206 T PT 158416206T PT 15841620 T PT15841620 T PT 15841620T PT 3193867 T PT3193867 T PT 3193867T
Authority
PT
Portugal
Prior art keywords
eye
drug
delivery
protection
anterior segment
Prior art date
Application number
PT158416206T
Other languages
English (en)
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of PT3193867T publication Critical patent/PT3193867T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
PT158416206T 2014-09-17 2015-09-17 Formulações oculares para administração de fármaco e proteção do segmento anterior do olho PT3193867T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051794P 2014-09-17 2014-09-17

Publications (1)

Publication Number Publication Date
PT3193867T true PT3193867T (pt) 2021-03-09

Family

ID=55453708

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158416206T PT3193867T (pt) 2014-09-17 2015-09-17 Formulações oculares para administração de fármaco e proteção do segmento anterior do olho

Country Status (19)

Country Link
US (5) US9814702B2 (pt)
EP (2) EP3878449A1 (pt)
JP (3) JP6657193B2 (pt)
KR (2) KR102450020B1 (pt)
CN (2) CN106999476B (pt)
AU (2) AU2015317531B2 (pt)
CA (1) CA2958315A1 (pt)
DK (1) DK3193867T3 (pt)
ES (1) ES2863601T3 (pt)
HU (1) HUE053852T2 (pt)
IL (2) IL282504B (pt)
MA (1) MA56220A (pt)
MX (2) MX2017003436A (pt)
NZ (1) NZ767710A (pt)
PL (1) PL3193867T3 (pt)
PT (1) PT3193867T (pt)
RU (2) RU2704810C2 (pt)
WO (1) WO2016044671A1 (pt)
ZA (1) ZA201701303B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102450020B1 (ko) * 2014-09-17 2022-09-30 팬옵티카, 인크. 약물 전달 및 전안부 보호를 위한 안구용 제제
JP7039606B2 (ja) * 2018-07-18 2022-03-22 温州医科大学 近視の治療方法及び薬物調製における応用
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053806A1 (fr) * 1997-05-26 1998-12-03 New Vision Co., Ltd. Compositions medicinales a administration topique renfermant les vitamines d et les vitamines k
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EA005859B1 (ru) * 2000-11-28 2005-06-30 Пфайзер Продактс Инк. Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
WO2006055526A2 (en) * 2004-11-16 2006-05-26 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007041499A2 (en) * 2005-09-30 2007-04-12 Lipoprotein Technologies, Inc. Cox inhibitor and nicotinic acid compositions and methods
WO2009129859A1 (en) * 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
MX2011008680A (es) * 2009-03-03 2011-09-08 Alcon Res Ltd Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
CA2770894A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
US20120277180A1 (en) * 2009-09-30 2012-11-01 Vitapath Genetics, Inc Cofactors and Methods for Use for Individuals
CA2805874A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2012024298A1 (en) * 2010-08-17 2012-02-23 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012162627A1 (en) * 2011-05-26 2012-11-29 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
EP2779994B1 (en) * 2011-11-15 2020-02-19 Allergan, Inc. Suspensions of cyclosporin a form 2
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
EP2968650B1 (en) * 2013-03-14 2019-01-16 PanOptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye
KR102450020B1 (ko) * 2014-09-17 2022-09-30 팬옵티카, 인크. 약물 전달 및 전안부 보호를 위한 안구용 제제

Also Published As

Publication number Publication date
KR20170058976A (ko) 2017-05-29
BR112017005523A2 (pt) 2017-12-05
CN113209000A (zh) 2021-08-06
US20160074371A1 (en) 2016-03-17
RU2017112930A (ru) 2018-10-17
RU2704810C2 (ru) 2019-10-31
IL251019A0 (en) 2017-04-30
RU2768652C1 (ru) 2022-03-24
US20210275501A1 (en) 2021-09-09
NZ729142A (en) 2023-08-25
JP6890692B2 (ja) 2021-06-18
ES2863601T3 (es) 2021-10-11
PL3193867T3 (pl) 2021-07-12
MX2021006070A (es) 2021-07-06
JP7176042B2 (ja) 2022-11-21
AU2015317531A1 (en) 2017-03-09
AU2021200997B2 (en) 2023-02-02
WO2016044671A1 (en) 2016-03-24
KR102450020B1 (ko) 2022-09-30
US20180078531A1 (en) 2018-03-22
US9623011B2 (en) 2017-04-18
AU2021200997A1 (en) 2021-03-11
HUE053852T2 (hu) 2021-07-28
JP2020079274A (ja) 2020-05-28
ZA201701303B (en) 2021-07-28
MA56220A (fr) 2022-04-20
CA2958315A1 (en) 2016-03-24
EP3193867A1 (en) 2017-07-26
JP6657193B2 (ja) 2020-03-04
EP3193867A4 (en) 2018-05-02
JP2017527600A (ja) 2017-09-21
CN106999476B (zh) 2021-05-04
US20190314343A1 (en) 2019-10-17
US9814702B2 (en) 2017-11-14
US20160206599A1 (en) 2016-07-21
NZ767710A (en) 2023-09-29
IL251019B (en) 2021-05-31
KR102555091B1 (ko) 2023-07-13
IL282504B (en) 2022-08-01
DK3193867T3 (da) 2021-04-06
JP2021121624A (ja) 2021-08-26
RU2017112930A3 (pt) 2019-04-11
AU2015317531B2 (en) 2020-11-19
CN106999476A (zh) 2017-08-01
US10183014B2 (en) 2019-01-22
EP3193867B1 (en) 2021-01-20
IL282504A (en) 2021-06-30
MX2017003436A (es) 2017-07-28
KR20220137157A (ko) 2022-10-11
EP3878449A1 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
IL252159A0 (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
GB201913962D0 (en) Ophthalmic drug compositions
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
PL3500255T3 (pl) Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania
IL282504A (en) Ocular formulations for drug administration and protection of the front part of the eye
EP3310356A4 (en) Compositions for the improvement of distance vision and the treatment of refractive errors of the eye
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
GB2568579B (en) Ophthalmic drug compositions
IL272601A (en) Pharmaceutical preparations for the treatment of ophthalmic conditions
EP3481411A4 (en) TREATING GLAUCOMA AND OTHER EYE DISEASES
GB2541840B (en) Ophthalmic composition for the treatment of ocular infection
IL270159B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
RS60926B1 (sr) Oftalmološka kompozicija za zaštitu rožnjače
EP2950782A4 (en) RETARD FORMULATIONS FOR THE TREATMENT OF INTRAOCULAR PRESSURE OR GLAUCOMA
IL265677A (en) Formulation of a controlled-release ophthalmic drug and its uses
EP3170500A4 (en) Prophylactic or therapeutic agent for diseases of posterior segment of eye